Filing Summary
Entity and period: The supplied filing is Flex Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016, not a filing identified as Decoy Therapeutics Inc. Investors should verify the company and filing match their intended research.
Business Context
Flex Pharma was a development-stage biotechnology company pursuing treatments for muscle cramps and spasms, and preparing to launch a consumer product for exercise-associated cramps. It reported no revenue through the quarter. Management expected the consumer product launch in Q2 2016.
Financial Results and Liquidity
| Metric | Q1 2016 | Q1 2015 or prior-period balance |
|---|---|---|
| Revenue | None | None to date |
| Research and development expense | $4.39 million | $2.80 million |
| Selling, general and administrative expense | $5.11 million | $3.22 million |
| Cost of production | $0.20 million | None |
| Operating loss | $9.70 million | $6.02 million |
| Net loss | $9.59 million | $6.02 million |
| Basic and diluted loss per share | $0.61 | $0.59 |
| Operating cash flow | $(9.17) million | $(4.14) million |
| Cash and cash equivalents | $54.00 million | $66.69 million at Dec. 31, 2015 |
| Marketable securities | $30.38 million | $26.97 million at Dec. 31, 2015 |
| Total liabilities / long-term debt | $3.08 million / no long-term debt | $2.88 million / no long-term debt |
Cash, cash equivalents and marketable securities totaled $84.38 million at quarter-end; current assets were $86.48 million versus current liabilities of $3.04 million. No profit margin is meaningful because the company had no revenue. Net loss increased about $3.57 million year over year as operating expenses rose; interest income partly offset the loss. Cash declined $12.69 million during the quarter, while investing cash use primarily reflected net purchases of marketable securities and equipment.
Material Changes and Unusual Items
- R&D expense rose $1.58 million, principally from preclinical and clinical work, including FLX-787 studies outside the United States, and higher personnel costs.
- SG&A increased $1.90 million, reflecting added personnel and consumer-brand development, marketing and pre-launch activity.
- The company recorded a $185,298 inventory write-off related to the initial consumer-product production run and ended the quarter with $112,569 of inventory.
- Q1 2015 cash flow included approximately $79.9 million of net IPO proceeds; Q1 2016 financing cash flow was only $7,594.
Outlook, Commentary and Risks
Management said existing cash and securities were expected to fund its current operating plan for at least 12 months, and separately projected funding through mid-2018 based on its development and launch assumptions. The company anticipated continued operating losses, rising R&D and commercial expenses, and a need for additional capital. It cautioned that funding might not be available on acceptable terms.
Management reported positive results from a blinded, controlled nocturnal-leg-cramp study of its extract formulation, including a median reduction of six cramps over two weeks versus four on vehicle control. A further study using a single-molecule TRP activator was expected later in 2016, with results anticipated in the first half of 2017; formal clinical trials were expected to follow an IND filing. These are company-reported early-stage findings and plans, not assurance of approval or commercial success.
Key risks include clinical and regulatory uncertainty, consumer-product launch and demand, inventory obsolescence, and dependence on a sole-source co-packer and certain sole-source suppliers. The filing reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls.
Important Facts to Verify
- Confirm the filing issuer is Flex Pharma, Inc., rather than Decoy Therapeutics Inc.
- Check whether the Q2 2016 consumer-product launch occurred as planned and whether sales, distribution and inventory performance supported management’s assumptions.
- Review subsequent clinical results, IND timing and regulatory developments for the drug candidates.
- Assess cash burn and financing needs against the stated mid-2018 runway, including whether additional capital was raised.
- Verify supply continuity and the status of sole-source manufacturing and raw-material arrangements.